首页> 外文期刊>Progress in Neuro-Psychopharmacology & Biological Psychiatry: An International Research, Review and News Journal >Predictive validity of a MK-801-induced cognitive impairment model in mice: Implications on the potential limitations and challenges of modeling cognitive impairment associated with schizophrenia preclinically
【24h】

Predictive validity of a MK-801-induced cognitive impairment model in mice: Implications on the potential limitations and challenges of modeling cognitive impairment associated with schizophrenia preclinically

机译:MK-801诱导的小鼠认知障碍模型的预测有效性:对临床前与精神分裂症相关的认知障碍建模的潜在局限性和挑战的影响

获取原文
获取原文并翻译 | 示例
       

摘要

Cognitive impairment associated with schizophrenia (CIAS) is a major and disabling symptom domain of the disease that is generally unresponsive to current pharmacotherapies. Critically important to the discovery of novel therapeutics for CIAS is the utilization of preclinical models with robust predictive validity. We investigated the predictive validity of MK-801-induced memory impairments in mouse inhibitory avoidance (MK-IA) as a preclinical model for CIAS by investigating compounds that have been tested in humans, including antipsychotics, sodium channel blocker mood stabilizers, and putative cognitive enhancers. The atypical antipsychotic clozapine, as well as risperidone and olanzapine (see Brown et al., 2013), had no effect on MK-801-induced memory impairments. For sodium channel blockers, carbamazepine significantly attenuated memory impairments induced by MK-801, whereas lamotrigine had no effect. Nicotine, donepezil, modafinil, and xanomeline all significantly attenuated MK-801-induced memory impairments, but the magnitude of effects and the dose-responses observed varied across compounds. Clinically, only acute administration of nicotine has demonstrated consistent positive effects on CIAS, while inconsistent results have been reported for lamotrigine, donepezil, and modafinil; atypical antipsychotics produce only moderate improvements at best. A positive clinical signal has been observed with xanomeline, but only in a small pilot trial. The results presented here suggest that the MK-IA model lacks robust predictive validity for CIAS as the model is likely permissive and may indicate false positive signals for compounds and mechanisms that lack clear clinical efficacy for CIAS. Our findings also highlight the potential limitations and challenges of using NMDA receptor antagonists in rodents to model CIAS.
机译:与精神分裂症(CIAS)相关的认知障碍是该疾病的主要致残症状域,通常对当前的药物治疗无反应。对于发现CIAS新疗法至关重要的是,利用临床前模型和可靠的预测有效性。我们通过研究已在人体中测试过的化合物(包括抗精神病药,钠通道阻滞剂情绪稳定剂和推定的认知功能),研究了MK-801诱导的记忆障碍在小鼠抑制回避(MK-IA)中作为CIAS的临床前模型的预测有效性。增强剂。非典型的抗精神病药物氯氮平,利培酮和奥氮平(参见Brown等人,2013年)对MK-801引起的记忆障碍无影响。对于钠通道阻滞剂,卡马西平显着减弱了由MK-801引起的记忆障碍,而拉莫三嗪则没有作用。尼古丁,多奈哌齐,莫达非尼和塞诺美林均能显着减轻MK-801引起的记忆障碍,但所观察到的作用强度和剂量反应因化合物而异。在临床上,仅尼古丁的急性给药对CIAS表现出一致的积极作用,而拉莫三嗪,多奈哌齐和莫达非尼的结果不一致。非典型抗精神病药最多只能产生中等程度的改善。用Xanomeline观察到阳性临床信号,但仅在一项小型试验中。此处提出的结果表明,MK-IA模型可能缺乏针对CIAS的可靠预测性,因为该模型可能是允许的,并且可能表明化合物和机制缺乏对CIAS明确临床效力的假阳性信号。我们的发现还突出了在啮齿动物中使用NMDA受体拮抗剂来模拟CIAS的潜在局限性和挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号